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ABSTRACT
This is a case report on a patient with non-dialysis chronic kidney disease (CKD) in whom several nutritional is-
sues are briefly discussed from a practical point of view. The article is accompanied by an editorial published 
in this Journal in relation to the 2nd International Conference of the European Renal Nutrition working group at 
ERA-EDTA—“Retarding CKD progression: readily available through comprehensive nutritional management?”—
and focuses on several practical topics associated with the nutritional approach for the conservative treatment 
of non-dialysis CKD. The article is divided into 3 sections—basic nutritional assessment, nutritional targets, and 
nutritional follow-up in non-dialysis CKD—linked to 3 consecutive steps of the clinical follow-up of the patient and 
the related nutritional concerns and intervention.
First visit: Baseline nutritional assessment and basic nutritional considerations in non-dialysis chronic kidney 
disease (CKD)
• What nutritional assessment/monitoring for protein-energy wasting (PEW) should be employed?
• Is a body mass index (BMI) of 21 kg/m2 adequate?
• What phosphate target should be pursued?
• What are the nutritional habits in patients with incident CKD?
• What protein needs and amount of dietary protein should be pursued?
• Does the quality of protein matter?
• What amount of dietary salt should be employed? How should this be obtained?
• How should normal serum phosphate be achieved?
• What diet should be recommended? Is a vegetarian diet an option?
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Second visit: Major nutritional targets in non-dialysis CKD
• Consequences of unintentional weight loss 
• What is the role of the renal dietitian in helping the patient adhere to a renal diet?
Intermediate visits: Nutritional follow-up in non-dialysis CKD
• What treatment for calcium/parathyroid hormone (PTH) will affect CKD progression?
Final visits:
• Would a dietary recall/intensive dietary education improve adherence with the diet?
• Would a very-low-protein diet (VLPD)/ketodiet be indicated for this patient?
Keywords: Chronic kidney disease, Conservative treatment, Ketoanalogs, Low protein diet, Nutrition, Point of 
care, Progression, Protein-energy wasting
Case report
A 64-year-old male nonsmoker had CKD. In the patient’s 
family, there was a history of diabetes mellitus (DM) but no 
end-stage renal disease (ESRD) had been reported. Fourteen 
years previously, the patient had been diagnosed with type 2 
DM, and had been on insulin treatment for 10 years; DM was 
complicated by peripheral neuropathy and retinopathy. The 
patient had had hypertension for 15 years and had hepatitis 
C virus-related chronic liver disease. At the first visit, the pa-
tient was admitted to the CKD nephrology clinic and underwent 
comprehensive, multifactorial nephrology care, including nutri-
tional treatment; several nutritional concerns were raised dur-
ing the follow-up and specific nutritional interventions were ap-
plied. These nutritional queries are highlighted in the following.
First visit (admission to CKD clinic: Tab. I)
• Weight: 71 kg; height: 180 cm; BMI: 21.9 kg/m2
• Blood pressure (BP): 170/100 mm Hg (supine and standing); 
heart rate: 80 bpm
• No edema; no dyspnea; no lung fluids
• Ultrasound: kidneys with low-normal size (longitudinal diam-
eter: R: 100 mm; L: 102 mm), mild reduction of cortico-medul-
lary differentiation
• Fundus oculi: proliferative diabetic retinopathy
• Echocardiography: mild left ventricular hypertrophy, ejection 
fraction: 55%
• Renal function: serum creatinine 2.93 mg/dL, estimated glo-
merular filtration rate (GFR) 24 mL/min/1.73 m2, urine albumin 
300 mg/dL (CKD stage 4)
• Multidrug treatment:
✓ Furosemide 50 mg, OID
✓ Irbesartan 300 mg, OID
✓ Amlodipine 5 mg, OID
✓ Nebivolol 5 mg, OID
✓ Fast insulin 4+12+10 U/d
✓ Retard insulin 26 UI/bedtime
Baseline nutritional assessment and basic nutritional 
considerations in non-dialysis CKD
✓  At the basal evaluation, major concerns were uncontrolled BP 
(despite consumption of 3 BP-lowering drugs plus furosemide) 
and moderate proteinuria (despite the patient was treated with 
ATII blockade)
✓  After undergoing 24 urine tests, albuminuria was 2.2 g/d, esti-
mated protein intake was approximately 1 g/kg/d, and salt in-
take was very high (about 15 g/d)
✓ Nutritional considerations:
°  Low body weight/BMI as compared to guidelines (ideal body 
weight [BMI 23] = 74.5 kg)
°  Hyperphosphatemia
°  High blood pressure and proteinuria, which may relate to 
nutrient intake (salt and proteins)
Intervention
✓ Low-protein diet, 0.6 g/kg/d, mixed proteins, 30 kcal/kg/d
✓ Low-sodium diet, 6 g/d salt
✓ Angiotensin-converting-enzyme inhibitor, ramipril 5 mg OID
What nutritional assessment/monitoring for PEW 
should be employed?
The available recommendations for the assessment of 
nutritional status in CKD/ESRD are toward an integrated ap-
proach to nutritional status evaluation (1-4), which combines 
evaluation of body mass and anthropometric parameters, 
biochemistry, and dietary intake assessment. The Interna-
tional Society of Renal Nutrition and Metabolism (ISRNM) 
recommend the diagnosis of PEW to be established by the 
presence of at least one criterion in 3 out of 4 categories of 
nutritional variables (1) (Tab. II).
Laboratory markers have a strong relation to mortality; 
however, both albumin and prealbumin can be largely influ-
enced by non-nutritional factors, such as inflammation (3-5). 
Assessment of body mass is widely used and unintentional 
body weight fluctuations in a short time suggest a high risk 
for PEW (1, 6).
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Assessment of skeletal muscle mass may provide the 
most reliable information for PEW diagnosis and monitoring 
(1). Assessment through the currently available gold standard 
imaging methods (magnetic resonance imaging, computed 
tomography, dual-energy X-ray absorptiometry) is expensive 
and/or not suitable for serial routine use. Body mass index 
does not distinguish between muscle and fat masses and is 
not a reliable tool. Anthropometric methods, such as assess-
ment of skin fold thickness and circumferences or bioelectric 
impedance analyses (BIA), can be an option if performed by 
well-trained professionals (7).
In addition, assessment of dietary history and self-reports 
of appetite are critical to evaluate the adequacy of nutrient 
intake. The application of tools for periodic appetite assess-
ment and food diaries also allows early intervention when di-
etary intake of protein and energy is lower than recommend-
ed (<0.8 g/kg/d and < 30 kcal/kg/d, respectively) (1, 3-6).
Is a BMI of 21 kg/m2 adequate?
While BMI is an excellent risk stratification tool in the com-
munity, its accuracy in assessing nutritional status and risk of 
malnutrition in catabolic diseases such as CKD is debatable. 
The limitations of BMI as a nutritional assessment tool in CKD 
TABLE I - Case report: clinical and laboratory data during the follow-up
Parameter Baseline Month 3 Month 4 Month 6 Month 9 Month 12
Weight, kg 71 65 72 ↑ 71 72
BMI, kg/m2 21.9 20.1 ↓ 22.1 ↑ 21.9 22.1
Blood pressure, mm Hg 170/100 146/92 ↓ 134/86 140/92 140/84
Creatinine, mg/dL 2.93 2.82 2.92 3.09 3.51 ↑
BUN, mg/dL 64.4 87.7 ↑ 56.9 ↓ 58.3 78.9 ↑
Sodium, mEq/L 135 143 142 141 138
Potassium, mEq/L 4.8 4.5 4.7 4.5 4.7
eGFR, mL/min 24 25 23 21 18 ↓
Hemoglobin, g/dL 14.4 13.5 13.0 12.7 11.6
Calcium, mg/dL 9.7 8.9 8.2 ↓ 9.1 9.0
Phosphorus, mg/dL 5.5 5.0 4.5 4.6 5.2 ↑
PTH, pg/mL 60 118 160 ↑ 65 ↓ 106
Albumin, g/dL 4.7 3.8 4.2 4.0 4.1
Albumin, g/d 2.2 1.6 ↓ 1.2 0.7 ↓ 0.5
Creatinine, mg/d 1590
Protein intake, g/d-g/kg/d 74-0.96 88-1.13 (↑) 0.68 (↓) 0.82 0.86 1.08 ↑
Sodium intake, mEq/d 270 170 ↓ 138 134 142 185 ↑
BMI = body mass index; BUN = blood urea nitrogen; eGFR = estimated glomerular filtration rate; PTH = parathyroid hormone.
TABLE II - Criteria for the diagnosis of protein-energy wasting 
1) Reduced levels of biochemical markers of nutritional status such as pre-albumin (<28 mg/dL), albumin (<3.8 g/dL), and cholesterol
2)  Reduced body mass: body mass index <23 kg/m2 or unintentional weight loss of >5% in 3 months or 10% in 6 months, reduced fat mass 
<10%)
3)  Reduced muscle mass: reduction of muscle mass by 5% in 3 months or 10% in 6 months, reduced arm muscle area by 10% as compared to 
the 50th percentile of the reference population
4)  Inadequate nutritional intake: spontaneous intake of protein and calories of <0.8 g/kg/d and <25 kcal/kg/d, respectively, for at least 2 
months
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include the inability to differentiate between body composi-
tion compartments (fat, muscle, and bone) or body fat distri-
bution (abdominal vs peripheral) and to account for differ-
ences related to age, sex, ethnicity, and physical fitness. Of 
significance in most settings, BMI is importantly confounded 
by fluid retention. The ISRNM proposed a BMI lower than 23 
kg/m2 as a criterion in the diagnosis of PEW (1). The sugges-
tion of this specific cutoff, besides not being an established 
WHO BMI risk stratum, was based on the mortality prognos-
tication of BMI in a large cohort of US dialysis patients (8). 
There are two hindrances in this cutoff:
1)  It assumes that a BMI below this limit is undernutrition, 
but a study from Brazil showed that patients with CKD with 
a BMI below 23 kg/m2 did not present any specific signs of 
PEW and their muscle function was similar to their coun-
terparts (9)
2)  It assumes that a BMI above that limit is good nutritional 
status; nevertheless, obesity per se represents a nutrition-
al disorder (by overnutrition).
In addition, obesity is not unequivocally exempt from 
PEW; malnutrition and inflammation-induced hypercatabo-
lism also coexist in these individuals, and obese sarcopenia, 
that is, diminished muscle mass in obese individuals, should 
not be ruled out (10).
While this BMI is not abnormally low for the patient’s 
ideal BMI, it is probably not sufficient to make a diagnosis. 
Information on other nutritional indicators is needed. Recent 
weight loss is diagnostically more useful than a single BMI 
value, and whenever possible analysis of body composition 
by BIA or skin fold thickness can provide a more accurate as-
sessment of the presence and nature of the PEW (11).
What phosphate target should be pursued?
Phosphate metabolism is crucial in the pathophysiology 
of CKD mineral and bone disorder (MBD) and vascular calci-
fication. High phosphate levels have been consistently asso-
ciated with unfavorable outcomes in patients with CKD, but 
several limitations hamper a definition of the optimal targets 
of phosphate serum levels (12). Nonetheless, hyperphospha-
temia is a late marker of phosphate overload.
The patient in this case had high serum phosphorus, out 
of range of the degree of CKD, in the presence of normal 
levels of calcium and PTH. Current guidelines suggest initiat-
ing dietary and pharmacologic approaches to reduce it (13). 
Specifically, Kidney Disease/Improving Global Outcomes 
(KDIGO) guidelines recommend limiting dietary phosphate 
intake and using phosphate-binding agents in order to reach 
and maintain phosphorus in the normal range (4.0-4.5 mg/
dL). However, the concomitant normality of PTH value rea-
sonably suggests that CKD-MBD is of relatively minor sever-
ity. Indeed, high phosphorus levels have a greater negative 
effect on cardiorenal prognosis when the compensatory in-
crease of PTH is fully displayed (14, 15). On the other hand, 
it is possible that the elevated phosphorus be at least in part 
a consequence of albuminuria (>2 g/24 h in this patient); a 
recent multifaceted study, including experimental and clini-
cal research, has in fact disclosed increased tubular reab-
sorption of phosphorus linked to abnormal urinary albumin 
excretion (16).
With the above considerations in mind, in moderate 
CKD in the presence of normal serum phosphate, it seems 
wise to postpone therapy with phosphorus-binding drugs 
while starting a soft approach to hyperphosphatemia (Tab. 
III) (17).
What are the nutritional habits in patients with inci-
dent CKD?
The nutritional habits in patients with incident CKD largely 
depend on the level of residual renal function. In early CKD, 
dietary intake is usually normal. In Western countries, aver-
age protein and salt intake, however, overcome the values 
recommended for the general population, and the phosphate 
intake is high. In addition, the widespread use of processed 
foods causes extra phosphate and sodium intake, very com-
monly among low-income patients. This type of diet impairs 
effectiveness of renin-angiotensin-aldosterone system inhibi-
tors and antihypertensive drugs, increases proteinuria, and 
contributes to overt CKD-MBD and metabolic acidosis.
When residual renal function is severely reduced, the 
above-mentioned uncontrolled usual diet induces retention 
of nitrogen-derived toxins, which in turn causes loss of ap-
petite, taste abnormality, or anorexia, leading to low food in-
take. Hence it is likely to result in low energy intake coupled 
with low protein intake, without any protein selection, so that 
the essential aminoacid supply is inadequate. This scenario is 
a high risk of PEW (18).
This patient at baseline had a very high sodium intake 
(roughly 15 g of salt intake) with a protein intake above the 
lower suggested level (0.8 g/kg/d). It is remarkable that phos-
phatemia is very high in respect to residual renal function 
and to the estimated protein intake: it suggests a large use 
of processed foods with phosphate-containing preservatives. 
The high salt intake may be in accordance with this type of 
dietary habit.
TABLE III - A soft approach to hyperphosphatemia
1)  Increase efficiency of antialbuminuric therapy by means of low-salt diet and, in the case of poor response, dual blockade of renin-angio-
tensin system
2) Reduce protein intake to normal (0.8 g/kg/d) that per se limits phosphate intake to 700-800 mg/d
3)  Provide nutritional counseling specifically aimed at limiting useless and hidden phosphate loads (cola drinks, processed sausages and 
cheese, industrial food with phosphorus-containing additives) and at reducing phosphorus content in both vegetable- and animal-derived 
products by preferring boiling as type of cooking (it causes demineralization of food that is proportional to the amount of used water and 
cooking time)
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What protein needs and amount of dietary protein 
should be pursued?
The uremic state is characterized by the retention of 
waste products and toxins resulting from protein catabolism 
and excreted with the urine; the low-protein diet, by lowering 
the dietary intake of protein, counterbalances such metabolic 
derangements, ameliorating several uremic symptoms and 
complications. In addition, due to the effects on glomerular 
hemodynamics, the low-protein diet may help to slow the 
progressive GFR decline. Overall, protein restriction is able to 
delay the start of chronic dialysis. As a result, dietary protein 
restriction is the heart of the nutritional therapy for CKD. Nev-
ertheless, a consensus on the level of GFR and when to start 
a low-protein diet and the optimal dietary protein amount or 
quality across the CKD stages has not been reached.
In the general population, the minimum recommended 
dietary allowance for proteins is 0.8 g/kg body weight/d (19); 
the protein intake in developed countries, however, is much 
higher, reaching 3.0 g/kg/d (20). Indeed, in Italy, the mean 
protein intake is 1.3±0.6 g/kg/d, with 3/4 individuals exceed-
ing the recommendation (21). Guidelines on renal disease 
advise 0.8 g/kg/d in all adults with GFR lower than 30 mL/
min/1.73 m2, and also recommend avoiding a protein intake 
higher than 1.3 g/kg/d in all patients at risk of CKD progres-
sion (22). Recommendations for patients in early CKD stages 
(1-3) or at low risk of progression are unclear. On this basis, it 
may be considered a safe, pragmatic approach to suggest that 
dietary advice established for the general population also suf-
fices most patients with CKD. At the first visit, a low-normal 
protein diet and counsel to avoid excessive intake of proteins 
should be suggested as a basic approach to all patients with 
CKD (23). Of note, in CKD stages 1-3, only 1 out of 2 patients 
complies with a 0.8 g/kg/d protein intake (24). In CKD more 
advanced than stage 3b, metabolic derangements and water 
retention rapidly worsen (25, 26), and a 0.8 g/kg/d diet is no 
longer effective to obtain striking metabolic and clinical con-
trol. At these CKD stages, it is required to adapt the dietary 
intakes to the impaired renal function and a more restricted 
nutritional treatment is needed.
In CKD stages 3b or advanced (as in this case), a protein 
prescription of 0.6-0.7 g/kg/d should improve uremia, meta-
bolic acidosis, and hyperparathyroidism (27). To avoid a nega-
tive nitrogen balance with such a reduced protein intake, at 
least 50% of proteins have to be of high biological value (i.e., 
meat, fish, eggs), and the energy intake should be normal-
high (30-35 kcal/kg/d) (23). Since adherence to nutritional 
therapy is low in CKD, only patients compliant with these low-
protein diets may be switched to more restricted, and poten-
tially more effective, dietary regimens.
Does the quality of protein matter?
The Kidney Disease Outcomes Quality Initiative guidelines 
state that when prescribing a low-protein diet, at least 50% 
to 75% of the protein should be of high biological value. A 
complete dietary pattern should include all the 8 essential 
aminoacids plus histidine in the case of renal failure. Lack of 
essential aminoacids in the human body compromises vital 
functions. When a protein contains all the essential aminoac-
ids in a proportion similar to that required by the body, it has 
a high biological value. When one or more of the essential 
aminoacids are missing or present in low amounts, the pro-
tein has a low biological value.
The biological value of a protein is indicated by a number 
from 100 to 0. More precisely, it is a measure of the percent-
age of the protein that is actually incorporated into the pro-
teins of the human body (Tab. IV). However, food preparation 
and cooking methods also have an impact on the biological 
value of protein and may denature some of the essential ami-
noacids.
What amount of dietary salt should be employed? 
How should it be obtained?
As depicted by 24-h urinary sodium excretion, the patient 
with CKD in this case is on a high-salt diet, with sodium in-
takes far above the recommended level for hypertensive pa-
tients by current guidelines (around 100 mmol/d; that is, 5-6 
g NaCl/d). The patient should reduce his salt intake. A large 
body of evidence supports the validity of lowering BP to pre-
vent cardiovascular disease in the general population. This is-
sue becomes even more critical in patients with CKD because 
they carry a greater cardiovascular risk across the entire 
spectrum of CKD stages (28). In these patients, achievement 
of lower BP levels also is fundamental to limit the progres-
sion of renal damage, especially in the presence of signifi-
cant proteinuria (as in this case). Although guidelines have 
repeatedly recommended in the last decade to intensively 
decrease BP in CKD, management of hypertension in patients 
with CKD remains inadequate. Armed with the knowledge of 
the extreme salt-sensitivity of BP in CKD as of the lower anti-
albuminuric efficacy of anti-Ras agents if salt intake is high, a 
low-salt diet should become the basic approach to CKD-relat-
ed hypertension (22). Indeed, besides the well-known low-
ering effectiveness of diuretic and anti-albuminuric therapy 
in the presence of unrestricted salt intake (as in this case), 
a normal sodium diet also precludes optimal control of BP 
during pharmacologic treatment with vasodilating agents (as 
in this case). Furthermore, about one-fourth of hypertensive 
patients with non-dialysis CKD have resistant hypertension 
(as in this case) (29). Resistant hypertension is defined by the 
persistence of office BP ≥130/80 mm Hg despite adherence to 
≥3 full-dose antihypertensive drugs including a diuretic or ≥4 
drugs regardless of BP level. This condition is more common 
TABLE IV - Biological value of protein
Protein food Biological value
Egg 94
Milk 90
Rice 83
Quinoa 83
Fish 76
Beef 74
Soybeans 73
Whole wheat 64
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in patients not adhering to a low-salt regimen and markedly 
increases the risk of cardiovascular and renal events.
Therefore, lowering salt intake, unless contraindicated (i.e., 
salt losers, volume depletion), is a cornerstone of conserva-
tive therapy in CKD (2). No large randomized study with hard 
endpoints has been conducted to date on this issue in patients 
with CKD to determine the optimal amount. However, while 
waiting for ad hoc trials in CKD, nephrologists should not give 
up with low-salt diet prescription but rather follow what renal 
pathophysiology teaches and make efforts to broaden imple-
mentation of this nonpharmacologic intervention in hyper-
tensive patients. Rather than pursuing a specific level of salt 
intake, it is important to introduce a gradual, stepwise sodium 
reduction aiming at around 5 g/d, as recommended by the US 
Institute of Medicine (30). Tips to reduce salt are many (28): 
monitor salt intake (daily salt intake [g] = 24 urinary sodium ex-
cretion [mmol]/17); communicate to the patient the daily salt 
intake estimated by 24-h urinary sodium excretion (target: 100 
mmol/d); move the salt shaker away from the table; cook pas-
ta, rice, and cereals without salt, and add it in smaller amounts 
directly to cooked food; use spices (e.g., herbs, lemon, vinegar, 
hot pepper) rather than salt or salt-containing condiments 
(e.g., ketchup, mayonnaise, mustard, barbecue sauce); decide 
what to eat by looking at the amount of sodium on food labels; 
choose fresh foods and low-salt bread; cut back on frozen din-
ners, canned soups, packaged mixes, and cured meat and fish 
(e.g., ham, bacon, anchovies, salmon); choose fresh (e.g., moz-
zarella) rather than seasoned cheese; rinse canned foods (e.g., 
tuna) to remove some sodium; and abolish salty snack foods 
(e.g., chips, nuts).
How should normal serum phosphate be achieved?
Clinical nephrologists routinely counteract the positive 
phosphate balance in patients with CKD through nutritional 
counseling and prescription of phosphate binders (31). Howev-
er, the superiority against placebo of phosphate control by diet 
or binders in terms of survival has never been tested in ran-
domized controlled trials (RCTs). There is a rationale support-
ing the value of a simultaneous intervention against phosphate 
overload in patients with CKD via the improvement of dietary 
intake and an individualized choice of phosphate binders (32).
In our patient with CKD, the choice of the phosphate 
binder is delicate. Calcium-based phosphate binder (calcium 
carbonate or acetate) should be limited (depending on PTH 
control and daily dietary calcium intake), since the patient has 
DM, a condition with an increased risk of developing vascular 
calcification. When serum phosphate levels are ≥5.5 mg/dL, 
a calcium-free phosphate binder may also be prescribed to 
help reduce serum phosphate, either alone or in combination 
with other phosphate binders.
What diet should be recommended? Is a vegetarian 
diet an option?
For this patient, a vegetarian diet could be an option. 
Vegetarian diets present some advantages in CKD-diabetic 
patients:
• Decrease in protein intake from animal origin is recom-
mended. Red meat is associated with risk of type 2 dia-
betes and greater risk of vascular disease and ESRD (33). 
In diabetic patients, a decrease in protein intake leads to 
a decrease in proteinuria. This effect is higher when sub-
stituting red meat with chicken and even more with a 
decrease in protein intake (34). The renal hemodynamic 
response to a protein meal in a subject with normal renal 
function is different when using animal or vegetarian pro-
tein (35).
• The intestinal absorption rate of phosphate is lower with 
plant protein. A decrease in meat processed food leads 
to a decrease in phosphate additives as well. A vegetar-
ian diet is associated with lower plasma phosphate and a 
decrease in FGF23 levels (36). 
• Vegetarian diets are associated with decreased acid load 
and acid production. A high intake of plant-based foods in 
patients with CKD renders an alkaline-rich diet. Plasma bi-
carbonate increases and renal excretion of acid decreases, 
which is associated with a lower risk of renal fibrosis and 
lower progression of renal insufficiency (37, 38).
• Beneficial effects of vegetarian diets on insulin resistance 
have been shown in several studies (39).
• Replacing a Western-style diet by a vegetarian diet style is 
probably too early in this patient. Changing eating habits 
requires a period of information and adaptation. Nutri-
tional preferences and capacity to adhere to the diet rec-
ommendations need to be checked before switching the 
patient to a vegetarian or low-protein diet with or without 
supplementation of aminoacids.
Second visit (3rd month during CKD follow-up: Tab. I)
• ↓ Blood pressure: 146/92 mm Hg
• ↓ Proteinuria: 1.6 g/d
• ↓↓ Weight: 65 kg; BMI: 20.1 kg/m2
• ↑ Blood urea nitrogen (BUN): 88 mg/dL
• ↑ Protein intake: 1.13 g/kg/d
• ↓ Sodium intake: 170 mEq/d
Major nutritional targets in non-dialysis CKD
✓  Three months after the introduction of a low-protein, normal-
protein, low-salt diet, a reduction of sodium intake was ob-
served with better control of BP and proteinuria
✓  The major nutritional concern was the striking reduction of 
body weight, though the protein intake seemed to be enhanced 
(BUN and urinary urea increased)
✓ Nutritional considerations:
°  In CKD, adherence to the dietary protein targets prescribed 
is low, but usually such intake is above the prescription
° In advanced CKD, energy intake is often reduced
°  A low energy intake in the presence of the minimum sug-
gested intake of proteins in CKD causes a negative nitrogen 
balance
° The benefits of lowering body weight are debatable
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Intervention
✓  Additional tests:
° Dietary diary and dietitian interview:
-  Protein intake 47 g/d, 0.60 g/kg/d (the patients is adherent 
to prescription)
-  Energy intake 1,375 kcal/d, <18 kcal/kg/d (↓↓ prescrip-
tion)
-  Assume only half of the prescribed olive oil (≈10% pre-
scribed energy)
-  Does not assume at all the protein-free food (≈30% pre-
scribed energy)
✓  Increase energy intake
✓  Dietary counseling and diet concordance
✓  Increase amlodipine to 10 mg, OID (moved to bedtime)
 
Consequences of unintentional weight loss
Any unintentional reduction in body weight should be tak-
en as a potential sign of PEW, requiring additional nutritional 
assessment and monitoring/follow-up. Unintentional weight 
loss is a common feature of all nutritional screening tools ap-
plied in clinical practice. Also in CKD, unintentional weight 
losses in a short period of time, even if only a couple of kilo-
grams, is associated with risk of adverse outcomes (40, 41).
Observational studies reported that in a predialysis, meta-
bolically healthy CKD population, overweight or obese individ-
uals had a significantly lower risk of all-cause mortality than 
normal weight patients but, in presence of metabolic syn-
drome, no difference in survival was observed. On the other 
hand, lower BMI is associated with greater mortality risk in 
patients with predialysis CKD; this relationship persisted when 
adjusted for malnutrition and inflammation markers (42).
No evidence exists that normal weight or leanness are fa-
vorable prognostic factors in the CKD population. Instead, an 
overweight condition seems to be preferable. Body weight loss 
is not a priority in absence of severe obesity and/or metabolic 
syndrome. Weight (fat mass) loss may be useful in patients 
with CKD mainly as a tool for correction of the associated car-
diovascular and renal risk factors (dyslipidemia, hypertension, 
proteinuria, inflammation, insulin resistance) (43).
Fatty mass loss should be encouraged by means of modifi-
cations of lifestyle, increase of physical activity, and limitation 
of energy intake excess. It is noteworthy that calorie restric-
tion increases protein requirements and then prevents nor-
mal adaptation to a low-protein diet. Hence, overweight or 
obese patients who are on a low-energy diet should not be 
prescribed protein-restricted (0.3-0.7 g/Kg/d) regimens. Con-
versely, when a low-protein diet is indicated, energy intake 
must equal or overcome energy requirements, even in the 
overweight or obese patient.
Regular physical exercise always should be recommended 
to prevent loss of lean body mass.
Nonsurgical weight loss interventions are able to reduce 
proteinuria and arterial blood pressure in patients with CKD 
and seem to reduce the progression of renal function decline 
(44). A careful valuation of potential benefits and risks is 
mandatory before performing bariatric surgery in the patient 
with CKD. Bariatric surgery normalizes GFR and reduces urine 
albumin excretion rate and arterial blood pressure levels in 
comorbid obese subjects with normal or increased GFR (44).
What is the role of the renal dietitian in helping the 
patient adhere to a renal diet?
The role of the dietitian is to translate the nephrologist’s 
prescription into recipes and meals so that the required re-
strictions are not a burden but a new eating style for the re-
nal patient. The nutritional intervention for patients with CKD 
should not be related only to the residual renal function but 
depends on many aspects such as socioeconomic, psycholog-
ical, and functional status (45, 46).
The first step for the renal dietitian is knowing the clini-
cal data of the patient but also his or her habits, both food 
and life, the environment in which he or she lives, and who 
takes care of him or her, regarding those involved in the prep-
aration of meals in particular so as to ensure an appropriate 
nutritional intervention without dramatically changing the 
patient’s habits and lifestyle. Another aspect the renal dieti-
tian knows is that the success of the nutritional intervention 
is conditioned by the presence and cooperation of family 
members or caregivers; their involvement in the counseling 
process is essential (Fig. 1).
When a dietitian starts a nutritional intervention, it is im-
portant to explain to the patient and relatives/caregivers that 
when we talk about diet we do not mean reducing energy 
intake, as this frequently has negative effects on nutritional 
status and metabolic control. We need to make it clear that 
we are referring mainly to qualitative changes aimed primar-
ily at reducing the burden of work for the kidney.
Finally, it is important to provide practical advice: no 
more structured dietary plans, nutritionally sound but com-
plex to realize, or long lists of foods to exclude (potassium, 
phosphorus, sodium, protein lists), but useful and simplified 
basic information on how to change habits and help patients 
combine ingredients to create enjoyable meals that fit rec-
ommendations for CKD (47-49).
 
Intermediate visits (4th and 6th months during CKD 
follow-up: Tab. I)
After 1 month, the patient again underwent dietary diary and di-
etitian interview:
✓ Protein intake 0.68 g/kg/d (adherent to prescription)
✓  Energy intake 1,945 kcal/d, 25 kcal/kg/d (↑↑ adherent to 
prescription)
After 2 more months, nutritional status was restored and some 
clinical changes occurred:
✓ Weight: 72 kg ↑; BMI: 22.2 Kg/m2
✓ BUN: 57 mg/dL ↑
✓ Blood pressure: 134/86 mm Hg ↓
✓ Serum Calcium: 8.2 mg/dL ↓
✓ PTH: 160 pg/mL ↑
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Nutritional follow-up in non-dialysis CKD
✓  After 6 months of nutritional interventions, the patient seems 
on effective nutrient intake, with stable nutritional status and 
no major metabolic derangements
✓ Calcium/phosphate/PTH metabolism remains to be improved
Intervention
✓ Paricalcitol, 1 μg OID
✓ Quarterly nutritional/dietitian monitoring planning
What treatment for calcium/PTH will affect CKD pro-
gression?
In the present case, the patient developed hyperphos-
phatemia, hyperparathyroidism, and mild hypocalcemia. 
Directly treating hyperphosphatemia should be the pri-
mary goal in the management of CKD-MBD abnormalities 
because this can reduce not only serum phosphorus, but 
also PTH and FGF-23 levels, which are directly involved in 
poor clinical outcome in patients with CKD (50). To sup-
port this approach, large epidemiologic studies consis-
tently show that high serum phosphorus levels are associ-
ü	Nephrologist dietary prescription
ü	Clinical data collection
ü	Dietary recall and collection of information on 
the environment in which the patient lives, social 
relationships, hobbies and interests
Involvement of persons who take 
care of the patient
Nutritional counseling:
ü	Clarifying the meaning of diet: not reduced energy intake but qualitative changes aimed primarily at 
reducing the burden of kidney work
ü	Give practical advice starting from the patient’s habits: no more structured  dietary plans,  
nutritionally sound but complex to realize or long lists of foods to exclude (potassium, phosphorus, 
sodium, protein list)
ü	Use of simple images could help patients retain the most important messages given during the 
counseling and remember them when at home
The goal: to translate the nephrologist’s prescription into recipes and meals so that the required restrictions 
are not a limitation but a new eating style for the renal patient
Follow-up:
–   First control: not later than 2–3 weeks from beginning of the nutritional therapy
–   Second should be 1 month later
–    Following visits: every 3 or more months, unless otherwise clinically indicated. The number of visits 
should be established based upon the severity of the disease: every month for  
ND-CKD stage 5, every 2 months for stage 4 and every 3-4 months for stage 3b [D’Alessandro, BCM 
Nephrol 2016]
Fig. 1 - Nutritional counseling for patients with chronic kidney disease: a hypothetical path for the renal dietitian
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ated with increased renal progression in CKD stage 3 to 
5 patients (51-54). This association between phosphorus 
and worse outcome has been extended to the general 
population, suggesting that high phosphate levels may 
impair renal health at all levels of kidney function (55). As 
a result of these findings, the KDIGO guidelines emphasize 
the need for treatment to normalize phosphorus levels in 
CKD stage 3 to 5 (13). Optimal phosphate control involves 
dietary measures, but these are not always sufficient, and 
it can also be needed to consider phosphate binder use. 
All the phosphate binders appear to be equivalent in their 
ability to control phosphate levels (50). With the limita-
tions inherent to the observational studies, we know 
that there is a correlation between renal calcium con-
tent and renal impairment in human renal biopsies (56). 
Moreover, at least in experimental studies, calcium-free 
phosphate binders stabilize renal function and attenuate 
kidney calcification (57, 58). Limited data from interven-
tional studies support these findings. In an independent 
study, a nonsignificant trend for dialysis inception was 
noted in the non-dialysis-dependent patients random-
ized to sevelamer compared to calcium carbonate (59). 
In a randomized clinical trial comparing calcium acetate, 
lanthanum carbonate, sevelamer carbonate, and placebo, 
only patients treated with sevelamer showed a reduction 
in FGF-23, whereas treatment with calcium acetate in-
creased FGF-23 levels (50). Whereas the most beneficial 
approach in the management of CKD-MBD abnormalities 
for preventing renal progression is maintaining phosphate 
levels within target range, there is no convincing evidence 
for treating the mild hypocalcemia in patients with CKD. 
Data on calcium balance have shown that giving excessive 
amounts of calcium causes calcium retention, which may 
lead to vascular calcification, and possibly, to worse renal 
outcomes (60). In an observational study, the use of phos-
phate binders (type not specified) was linked to faster 
CDK progression (61), while in a randomized clinical trial 
comparing different phosphate binders, only a participant 
in the calcium acetate group experienced an episode of 
acute kidney injury (50). Moreover, calcium supplemen-
tation could also contribute to progressive renal injury 
in the general population. Among 1,675 healthy partici-
pants in an RCT of colorectal adenoma chemoprevention 
with calcium and vitamin D, daily supplementation with 
1,200 mg of elemental calcium caused a small but signifi-
cant increase in blood creatinine, which may have poten-
tial implications for clinical recommendations for calcium 
supplementations (62). In line with these findings, the 
KDIGO guidelines emphasize the need for restricting the 
dose of calcium-based phosphate binders, especially in 
the presence of vascular calcification, which is prevalent 
in patients with CKD (13).
Once the phosphorous level is on target range, our next 
goal should be treatment of hyperparathyroidism with vi-
tamin D or vitamin D analogues. Although the presence of 
high PTH levels have been described as an independent 
predictor of CKD progression, the effect of controlling hy-
perparathyroidism with vitamin D on renal progression 
has not been evaluated systematically (63). However, it is 
well-known that vitamin D may reduce proteinuria, a sur-
rogate marker of renal progression. A systematic review 
of RCTs has demonstrated the anti-proteinuric effect of 
active vitamin D (64). However, before starting active vi-
tamin D treatment, it seems reasonable to assess 25-hy-
droxyvitamin D levels and initiate replacement with native 
vitamin D if levels are low, as KDIGO guidelines suggest. 
The fact that the antiproteinuric effect of vitamin D has 
been also demonstrated after nutritional vitamin D sup-
plementation reinforces this approach (65). Regardless of 
the type of vitamin D provided, serum calcium and phos-
phorus levels need to be monitored closely to prevent hy-
percalcemia and hyperphosphatemia. This effect seems to 
be less important with paricalcitol (66). Whether vitamin 
D can slow CKD progression is not yet known.
Therefore, keeping in mind the potential renoprotec-
tive effect of controlling CKD-MBD disorders, it seems rea-
sonable for the present patient 1) to consider the use of 
a phosphate binder for controlling high phosphate levels, 
with a preferential use of a non-calcium-containing binder 
if vascular calcification is present; 2) to avoid the overuse 
of calcium-containing phosphate binders; and 3) to add 
vitamin D for reducing PTH (and proteinuria), with a pref-
erential use of paricalcitol when active vitamin D prepara-
tion is needed. Although there is no randomized clinical 
trial, an observational study has recently tested this ap-
proach, showing better outcome when we use a regimen 
based on the restricted use of calcium-based binders in 
combination with calcium-free phosphate binders, low-
dose nutritional vitamin D supplementation, and the use 
of paricalcitol as antiparathyroid agent, compared with 
unrestricted conventional care, in non-dialysis-dependent 
patients with CKD (67).
Final visits (9th and 12th months during CKD follow-
up: Tab. I)
• After 3 months:
✓ Patient was stable, well-being, good control of comorbidities
✓ No nutritional changes
✓ Improvement of PTH and proteinuria
✓ No intervention
• After 3 more months:
✓ Stable nutritional status (body weight, serum albumin)
✓ Stable clinical conditions and comorbidities
✓ Worsening of renal failure
✓ Reduced diet adherence:
°  Serum phosphate: 5.2 mg/dl ↑
°  Protein intake: 1.08 g/kg/d ↑
°  Sodium intake: 185 mEq/d ↑
• Intervention:
✓ Intensive dietitian intervention
✓ Consider a more restricted renal diet
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Would a dietary recall/intensive dietary education im-
prove adherence with the diet?
A careful evaluation of dietary habits is mandatory for 
an effective nutritional intervention. Dietary recalls (food 
diary, 3-day recall) are essential tools for the renal dieti-
tian to estimate habitual energy and nutrient intake, but 
they allow doing more. While collecting a dietary recall, 
one can obtain information about the patient’s life, prac-
tical aspects such who does the shopping and who pre-
pares meals, or the patient’s capacity to perform activities 
of daily living, social relationships, interests, and hobbies. 
This is important information to provide feasible dietary 
instructions not too far from the patient’s current dietary 
habits (23).
The timing of the visits is important to verify the effi-
cacy of the counseling and to strengthen some concepts as 
dietary recommendations in CKD are many. During the first 
visit, the dietitian gives the main instructions that need to 
be further clarified during the control visits. Blood and uri-
nary tests are essential to show the patients what is correct 
and what needs to be adjusted. Do not worry about repeat-
ing the same things. The goal of repetition is to find new so-
lutions together with the patient so that he or she perceives 
that what we ask is not an imposition but what is the best 
for improving his or her health/nutritional status. A key find-
ing to reach ample adherence to the low-protein diet is to 
individualize the dietary strategies and at the same time to 
build up specific intensive counseling/education programs 
for patients (68). The message for our patients is that we 
do not need the patient to follow the diet we prescribed 
perfectly but to work with us to find the best solution for re-
alizing a new style, which should be considered as a therapy 
to all effects (45, 47).
Would a VLPD/ketodiet be indicated for this patient?
The VLPD (0.3-0.4 g/kg body weight/d protein) is a 
vegetarian diet that mainly includes vegetables and fruits 
and is supplemented with essential aminoacids and keto-
acids (69). To maintain a neutral nitrogen balance, though 
the protein intake is below the minimum required thresh-
old, ketoacids are given to allow endogenous nitrogen 
recycling as a means of building the essential aminoac-
ids from the relative ketoacids, thus further contribut-
ing to reduce serum urea levels (70). Because of the very 
low nitrogen intake, a high energy intake (never lower 
than 30-35 kcal/kg/d) is mandatory to maintain a neu-
tral body nitrogen balance. Protein-free artificial foods 
can be added to this diet, helping to reach such a high 
energy supply, since these products provide high energy 
amounts (23).
The VLPD has been shown to have further additional 
positive effects, such as a lower indoxyl sulfate content 
compared to the usual low-protein diet (71), a reduced 
need for erythropoietin (72), better control of BP (73), 
lower urinary and plasma phosphate and FGF23 levels (74), 
lower proteinuria, and higher antiproteinuric response to 
renin-angiotensin system inhibitors (75). Also, vegetables 
and fruits increase plasma bicarbonate levels, improving 
the metabolic acidosis (38), and fiber intake, both being 
possibly related to a better CKD outcome. 
A major concern of the use of the VLPD is the nutri-
tional risk, since adherence to diet prescription in the CKD 
population is low. Protein metabolism and nitrogen bal-
ance adapt well in patients with CKD on a VLPD (up to 0.3 g 
protein/kg/d) when supplemented with ketoacids and in 
presence of high energy supply, allowing a neutral nitrogen 
balance in the short term (76, 77). Also in the long term 
(more than 1 year), the adaptive response to the reduced 
nitrogen load was similarly positive (78). Therefore, VLPDs 
are, theoretically, nutritionally safe during advanced CKD, 
given that an adequate amount of calories is provided. 
Clinical studies have shown that VLPD is safe during either 
the predialysis CKD period or during the following long-
term dialysis period for patients who previously received 
such a diet and were on dietitian control (79). Indeed, VLPD 
has recently received a final consensus from experts in this 
field (80).
Not every patient with CKD may benefit from a supple-
mented VLPD. A patient with progressive CKD (as in this 
case), proven high adherence to diet and acceptance of 
lifestyle changes (somewhat in this case), and a low rate 
or well-controlled comorbidities (as in this case) is likely 
to have a positive result from the VLPD (79, 81). A recent 
prospective RCT assessed the effectiveness and safety of a 
VLPD supplemented with ketoanalogs in reducing CKD pro-
gression in CKD stage 4-5 as compared to a conventional 
low-protein diet (81); these patients were highly selected, 
well-nourished, and well-adherent to the low-protein diet, 
and had low comorbidity levels. In these conditions, the 
ketodiet was effective and safe in deferring dialysis initia-
tion or reducing the rate of decline in renal function; the 
key points of such effects were careful patient selection and 
continuous nutritional monitoring and counseling. Hence, 
supplemented VLPD management requires high expertise 
by nephrologists and dietitians, good doctor-patient con-
cordance, family and social support, as well as high doctor-
patient empathy.
Acknowledgment
The European Renal Nutrition Working Group is an initiative of and 
supported by the European Renal Association-European Dialysis 
Transplant Association.
Disclosures
Financial support: No grants or funding have been received related 
to this study. 
Conflicts of interest: V. Bellizzi: Lectures, consulting and trav-
el grants Fresenius Kabi; consulting Shire; lecture Abbott. P. 
Chauveau: Lecture and travel grant Fresenius Kabi and Vifor. M. 
Cozzolino: Lectures Shire, AbbVie, Amgen. A. Cupisti: Lectures, 
consulting fees and travel grants Shire. L. De Nicola: Consulting and 
lectures AbbVie, Janssen, AstraZeneca. P. Molina: speaker hono-
raria from Abbott Nutrition and Vifor-Pharma-Fresenius Medical 
Care. D. Fouque: Lectures, consulting and travel grants Fresenius 
Kabi. The other authors did not declare any conflict of interest re-
lated to this study to disclose.
Retarding CKD progressione66 
© 2016 The Authors. Published by Wichtig International
References
1. Fouque D, Kalantar-Zadeh K, Kopple J, et al. A proposed nomen-
clature and diagnostic criteria for protein-energy wasting in 
acute and chronic kidney disease. Kidney Int. 2008;73(4):391-8.
2. Ikizler TA, Cano NJ, Franch H, et al. Prevention and treatment of 
protein energy wasting in chronic kidney disease patients: a con-
sensus statement by the International Society of Renal Nutrition 
and Metabolism. Kidney Int. 2013;84:1096-1107.
3. Cano N, Aparicio M, Brunori G, et al. ESPEN Guidelines on Paren-
teral Nutrition: Adult Renal Failure. Clin Nutr. 2009;28:401-414.
4. Cano N, Fiaccadori E, Tesisnsky P, et al. ESPEN Guidelines in En-
teral Nutrition: adult renal failure. Clin Nutr. 2006;25:295-310.
5. Kalantar-Zadeh K, Cano NJ, Budde K, et al. Diets and enteral sup-
plements for improving outcomes in chronic kidney disease. Nat 
Rev Nephrol. 2011;7:369-384.
6. Obi Y, Qader H, Kovesdy CP, Kalantar-Zadeh K. Latest consensus 
and update on protein-energy wasting in chronic kidney disease. 
Curr Opin Clin Nutr Metab Care. 2015;18:254-262.
7. Stenvinkel P, Carrero JJ, von Walden F, Ikzler TA, Nader GA. Mus-
cle wasting in end-stage renal disease promulgates premature 
death: established, emerging and potential novel treatment 
strategies. Nephrol Dial Transplant. 2016;31:1070-1077.
8. Kalantar-Zadeh K, Kopple JD, Kilpatrick RD, et al. Associa-
tion of morbid obesity and weight change over time with car-
diovascular survival in hemodialysis population. Am J Kidney 
Dis. 2005;46(3):489-500.
9. Leal VO, Moraes C, Stockler-Pinto MB, et al. Is a body mass index 
of 23 kg/m² a reliable marker of protein-energy wasting in hemo-
dialysis patients? Nutrition. 2012;28(10):973-7.
10. Carrero JJ, Avesani CM. Pros and cons of body mass index as a 
nutritional and risk assessment tool in dialysis patients. Semin 
Dial. 2015;28(1):48-58.
11. Carrero JJ, Wanner C. Clinical monitoring of protein-energy wast-
ing in chronic kidney disease: moving from body size to body 
composition. J Ren Nutr. 2016;26(2):63-4. 
12. Malindretos P, Cozzolino M. Phosphate binders, past-pres-
ent-future. A critical appraisal. Expert Opin Pharmacother. 
2016;17(3):297-300.
13. KDIGO Clinical Practice Guideline for the Diagnosis. Evaluation, 
prevention, and treatment of chronic kidney disease mineral and 
bone disorder (CKD-MBD). Kidney Int. 2009;76:S1-S130.
14. Slatopolsky E. The intact nephron hypothesis: the concept and its 
implications for phosphate management in CKD-related mineral 
and bone disorder. Kidney Int. 2011;121:S3-S8.
15. De Nicola L, Conte G, Chiodini P, et al. Interaction between phos-
phorus and parathyroid hormone in non-dialysis CKD patients 
under nephrology care. J Nephrol. 2014;27:57-63.
16. de Seigneux S, Courbebaisse M, Rutkowski JM, et al.; NephroTest 
Study Group. Proteinuria Increases Plasma Phosphate by Alter-
ing Its Tubular Handling. J Am Soc Nephrol. 2015;26:1608-18.
17. D’Alessandro C, Piccoli GB, Cupisti A. The “phosphorus pyramid”: 
a visual tool for dietary phosphate management in dialysis and 
CKD patients. BMC Nephrol. 2015;16:9. 
18. Kovesdy CP, Kopple JD, Kalantar-Zadeh K. Management of pro-
tein-energy wasting in non-dialysis-dependent chronic kidney 
disease: reconciling low protein intake with nutritional therapy. 
Am J Clin Nutr. 2013;97(6):1163-77.
19. Protein and aminoacid requirements in human nutrition. Report 
of a Joint FAO/WHO/UNU Expert Consultation. In: WHO Techni-
cal Report Series 935. 2007. Available at: who.int/iris/handle/10
665/43411#sthash.4pHKXPSr.dpuf.
20. Millward DJ. Optimal intakes of protein in the human diet. Proc 
Nutrition Soc. 1999;58:403-13.
21. Cirillo M, Lombardi C, Chiricone D, et al. Protein intake and kid-
ney function in the middle-age population: contrast between 
cross-sectional and longitudinal data. Nephrol Dial Transplant. 
2014;29:1733-40.
22. KDIGO Guidelines, Chapter 3. Management of progression and 
complications of CKD. Kidney Int. 2013;Suppl 3:73-90.
23. D’Alessandro C, Piccoli GB, Calella P, et al. “Dietaly”: practical 
issues for the nutritional management of CKD patients in Italy. 
BMC Nephrol. 2016;17(1):102.
24. De Nicola L, Chiodini P, Zoccali C, et al.; SIN-TABLE CKD Study 
Group. Prognosis of CKD patients receiving outpatient nephrol-
ogy care in Italy. Clin J Am Soc Nephrol 2011;6:2421-28.
25. Moranne O, Froissart M, Rossert J, et al.; NephroTest Study 
Group. Timing of onset of CKD-related metabolic complications. 
J Am Soc Nephrol. 2009;20:164-71.
26. Bellizzi V, Scalfi L, Terracciano V, et al. Early changes in bioelectri-
cal estimates of body composition in chronic kidney disease. J 
Am Soc Nephrol. 2006;17:1481-7.
27. Cianciaruso B, Pota A, Pisani A, et al. Metabolic effects of two low 
protein diets in chronic kidney disease stage IV-V: a randomized 
controlled trial. Nephrol Dial Transpl. 2008;23:636-44.
28. De Nicola L, Minutolo R, Bellizzi V, et al. Investigators of the Tar-
get Blood Pressure Levels in Chronic Kidney Disease (TABLE in 
CKD) Study Group. Achievement of target blood pressure lev-
els in chronic kidney disease: a salty question? Am J Kidney Dis. 
2004;43:782-95.
29. De Nicola L, Gabbai FB, Agarwal R, et al. Prevalence and prog-
nostic role of resistant hypertension in chronic kidney disease 
patients. J Am Coll Cardiol. 2013;61(24):2461-7.
30. Institute of Medicine. Strategies to reduce sodium intake in the 
United States. Washington, DC: National Academies Press; 2010.
31. Cozzolino M, Ureña-Torres P, Vervloet MG, et al; CKD-MBD Work-
ing Group of ERA-EDTA. Is chronic kidney disease-mineral bone 
disorder (CKD-MBD) really a syndrome? Nephrol Dial Transplant. 
2014;29(10):1815-20.
32. Galassi A, Cupisti A, Santoro A, Cozzolino M. Phosphate bal-
ance in ESRD: diet, dialysis and binders against the low evident 
masked pool. J Nephrol. 2015;28(4):415-29.
33. Lew QLJ, Jafar TH, Koh HWL, et al. Red meat intake and risk of 
ESRD. J Am Soc Nephrol. 2016;pii:ASN.2016030248.
34. de Mello VDF, Zelmanovitz T, Perassolo MS, et al. Withdrawal of 
red meat from the usual diet reduces albuminuria and improves 
serum fatty acid profile in type 2 diabetes patients with macroal-
buminuria. Am J Clin Nutr. 2006;83(5):1032-8.
35. Nakamura H, Yamazaki M, Chiba Y, et al. Acute loading with pro-
teins from different sources in healthy volunteers and diabetic 
patients. J Diabet Complications. 1991;5:140-142.
36. Moe SM, Zidehsaraj MP, Chambers MA, et al. Vegetarian com-
pared with meat dietary protein source and phosphorus ho-
meostasis in chronic kidney disease. Clin J Am Soc Nephrol. 
2011;6:257-264.
37. Scialla JJ, Lawrence LJ, Wolf M, et al. Plant protein intake is as-
sociated with fibroblast growth factor 23 and serum bicarbon-
ate levels in patients with CKD: the Chronic Renal Insufficiency 
Cohort Study. J Ren Nutr. 2012;22:379-388.
38. Goraya N, Simoni J, Jo C, Wesson DE. Dietary acid reduction with 
fruits and vegetables or bicarbonate attenuates kidney injury in 
patients with a moderately reduced glomerular filtration rate 
due to hypertensive nephropathy. Kidney Int. 2012;81:86-93.
39. Rizzo NS, Sabat e J, Jaceldo-Siegl K, Fraser GE. Vegetarian 
dietary pat- terns are associated with a lower risk of meta-
bolic syndrome: The Adventist Health Study 2. Diabetes Care. 
2011;34:1225-1227.
40. Cabezas-Rodriguez I, Carrero JJ, Zoccali C, et al. Influence of body 
mass index on the association of weight changes with mortality in 
hemodialysis patients. Clin J Am Soc Nephrol. 2013;8(10):1725-33.
41. Ahmadi SF, Zahmatkesh G, Ahmadi E, et al. Association of body 
mass index with clinical outcomes in non-dialysis-dependent 
Bellizzi et al  e67
© 2016 The Authors. Published by Wichtig International
chronic kidney disease: a systematic review and meta-analysis. 
Cardiorenal Med. 2015;6(1):37-49.
42. Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Paradoxical associa-
tion between body mass index and mortality in men with CKD 
not yet on dialysis. Am J Kidney Dis. 2007;49:581-591.
43. Teta D. Weight loss in obese patients with chronic kidney disease: 
who and how? J Ren Care. 2010;36 Suppl 1:163-71.
44. Navaneethan SD, Yehnert H, Moustarah F, et al. Weight loss inter-
ventions in chronic kidney disease: a systematic review and me-
ta-analysis. Clin J Am Soc Nephrol. 2009;4(10):1565-74.
45. Piccoli GB, Capizzi I, Vigotti FN, et al. Low protein diets in patients 
with chronic kidney disease: a bridge between mainstream 
and complementary-alternative medicines? BMC Nephrol. 
2016;17(1):76.
46. Santoro D, Ingegnieri MT, Vita G, et al. Socio-economic factors, 
food habits and phosphorus levels in patients on hemodialysis. 
Nephrourol Mon. 2015;7(4): e27114.
47. Pisani A, Riccio E, Bellizzi V, et al. 6-tips diet: a simplified dietary 
approach in patients with chronic renal disease. A clinical ran-
domized trial. Clin Exp Nephrol. 2016;20(3):433-42.
48. Ameh OI, Cilliers L, Okpechi IG. A practical approach to the nu-
tritional management of chronic kidney disease patients in Cape 
Town, South Africa. BMC Nephrol. 2016;17(1):68.
49. Mafra D, Leal VO. A practical approach to a low protein diet in 
Brazil. BMC Nephrol. 2016;17(1):105.
50. Block GA, Wheeler DC, Persky MS, et al. J Am Soc Nephrol. 
2012;23(8):1407-15.
51. Bellasi A, Mandreoli M, Baldrati L, et al. Chronic kidney disease 
progression and outcome according to serum phosphorus in 
mild-to-moderate kidney dysfunction. Clin J Am Soc Nephrol. 
2011;6(4):883-91.
52. Zoccali C, Ruggenenti P, Perna A, et al;REIN Study Group. Phosphate 
may promote CKD progression and attenuate renoprotective effect 
of ACE inhibition. J Am Soc Nephrol. 2011;22(10):1923-30.
53. Chartsrisak K, Vipattawat K, Assanatham M, et al. Mineral me-
tabolism and outcomes in chronic kidney disease stage 2-4 pa-
tients. BMC Nephrol. 2013;14:14.
54. Caravaca F, Villa J, García de Vinuesa E, et al. Relationship be-
tween serum phosphorus and the progression of advanced 
chronic kidney disease. Nefrologia. 2011;31(6):707-15.
55. Sim JJ, Bhandari SK, Smith N, et al. Phosphorus and risk of re-
nal failure in subjects with normal renal function. Am J Med. 
2013;126(4):311-8.
56. Gimenez LF, Solez K, Walker WG. Relation between renal calcium 
content and renal impairment in 246 human renal biopsies. Kid-
ney Int. 1987;31(1):93-9.
57. Cozzolino M, Staniforth ME, Liapis H, et al. Sevelamer hydrochlo-
ride attenuates kidney and cardiovascular calcifications in long-
term experimental uremia. Kidney Int. 2003;64(5):1653-61.
58. Nagano N, Miyata S, Obana S, et al. Sevelamer hydrochloride, a 
phosphate binder, protects against deterioration of renal func-
tion in rats with progressive chronic renal insufficiency. Nephrol 
Dial Transplant. 2003;18(10):2014-23.
59. Di Iorio B, Bellasi A, Russo D; INDEPENDENT Study Investigators. 
Mortality in kidney disease patients treated with phosphate bind-
ers: a randomized study. Clin J Am Soc Nephrol. 2012;7(3):487-93.
60. Spiegel DM, Brady K. Calcium balance in normal individuals and 
in patients with chronic kidney disease on low- and high-calcium 
diets. Kidney Int. 2012;81(11):1116-22.
61. Boudville N, Kemp A, Moody H, et al; eKiDNAA. Factors associ-
ated with chronic kidney disease progression in Australian ne-
phrology practices. Nephron Clin Pract. 2012;121(1-2):c36-41.
62. Barry EL, Mott LA, Melamed ML, et al. Calcium supplementation 
increases blood creatinine concentration in a randomized con-
trolled trial. PLoS One. 2014;9(10):e108094.
63. Górriz JL, Molina P, Cerverón MJ, et al. Vascular calcification in pa-
tients with nondialysis CKD over 3 years. Clin J Am Soc Nephrol. 
2015;10(4):654-66.
64. de Borst MH, Hajhosseiny R, Tamez H, et al. Active vitamin D 
treatment for reduction of residual proteinuria: a systematic re-
view. J Am Soc Nephrol. 2013;24(11):1863-71.
65. Molina P, Górriz JL, Molina MD, et al. The effect of cholecalcif-
erol for lowering albuminuria in chronic kidney disease: a pro-
spective controlled study. Nephrol Dial Transplant. 2014;29(1): 
97-109.
66. Brown AJ, Finch J, Slatopolsky E. Differential effects of 
19-nor-1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin 
D(3) on intestinal calcium and phosphate transport. J Lab Clin 
Med. 2002;139(5):279-84.
67. Molina P, Gorriz JL, Juan I, et al. Effects of a regimen based on 
restricted calcium intake from phosphate binders, low dose vita-
min D supplementation, and paricalcitol, on survival, hospitaliza-
tion and renal progression. A prospective cohort study in non-
dialysis CKD patients (abs). Nephrol Dial Transpl. 2016;31(suppl 
1):i456-i457.
68. Paes-Barreto JG, Silva MI, Qureshi AR, et al. Can renal nutri-
tion education improve adherence to a low-protein diet in pa-
tients with stages 3 to 5 chronic kidney disease? J Ren Nutr. 
2013;23(3):164-71.
69. Barsotti G, Morelli E, Cupisti A, et al. A low-nitrogen low-phos-
phorus vegan diet for patients with chronic renal failure. Neph-
ron. 1996;74:390-4.
70. Walser M, Coulter AW, Dighe S, Crantz FR. The effect of ketoana-
logues of essential aminoacids in severe chronic uremia. J Clin 
Invest. 1973;52:2865-77.
71. Marzocco S, Dal Piaz F, Di Micco L, et al. Very low protein diet re-
duces indoxyl sulfate levels in chronic kidney disease. Blood Purif. 
2013;35:196-201.
72. Di Iorio BR, Minutolo R, De Nicola L, et al. Supplemented very 
low protein diet ameliorates responsiveness to erythropoietin in 
chronic renal failure. Kidney Int. 2003;64:1822-8.
73. Bellizzi V, Di Iorio BR, De Nicola L, et al; ERIKA Study Group. 
Very low protein diet supplemented with ketoanalogs improves 
blood pressure control in chronic kidney disease. Kidney Int. 
2007;71:245-51.
74. Di Iorio B, Di Micco L, Torraca S, et al. Acute effects of very-low-
protein diet on FGF23 levels: a randomized study. Clin J Am Soc 
Nephrol. 2012;7:581-7.
75. Di Iorio BR, Bellizzi V, Bellasi A, et al. Phosphate attenuates the 
anti-proteinuric effect of very low-protein diet in CKD patients. 
Nephrol Dial Transplant. 2013;28:632-40.
76. Masud T, Young VR, Chapman T, Maroni BJ. Adaptive responses 
to very low protein diets: the first comparison of ketoacids to es-
sential aminoacids. Kidney Int. 1994;45:1182-92.
77. Giordano C. Use of exogenous and endogenous urea for 
protein synthesis in normal and uremic subjects. J Lab Clin 
Med. 1963;62:231-46.
78. Tom K, Young VR, Chapman T, et al. Long-term adaptive respons-
es to dietary protein restriction in chronic renal failure. Am J 
Physiol Endocrinol Metab, 1995;268:E668-77.
79. Bellizzi V, Chiodini P, Cupisti A, e al. Very low-protein diet plus 
ketoacids in chronic kidney disease and risk of death during end-
stage renal disease: a historical cohort controlled study. Nephrol 
Dial Transplant. 2015;30:71-7.
80. Aparicio M, Bellizzi V, Chauveau P, et al. Keto acid therapy in pre-
dialysis chronic kidney disease patients: final consensus. J Ren 
Nutr. 2012;22 Suppl 2:22-4.
81. Garneata L, Stancu A, Dragomir D, et al. Ketoanalogue-Supple-
mented Vegetarian Very Low-Protein Diet and CKD Progression. J 
Am Soc Nephrol. 2016;27(7):2164-76.
